BC
COLL icon

Broadfin Capital’s Collegium Pharmaceutical COLL Stock Holding History

Broadfin Capital’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-297,200
Closed -$5.3M – 93
2015
Q2 		$5.3M Buy
+297,200
New +$5.14M 0.28% 74

Other funds holding COLL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Broadfin Capital's COLL Position: Q3 2015 in Review

Broadfin Capital sold out of Collegium Pharmaceutical (COLL) in Q3 2015, closing a stake of 297,200 shares — an estimated $5.3M sold.

Broadfin Capital first reported a position in COLL in Q2 2015 and held it in 1 quarter. The position peaked at $5.3M in Q2 2015. 49 funds tracked by Wall St. Rank hold COLL as of Q3 2015.

  • Broadfin Capital reported no remaining Collegium Pharmaceutical position as of Q3 2015 after selling out during the quarter.
  • Broadfin Capital sold 297,200 Collegium Pharmaceutical shares in Q3 2015, an estimated $5.3M.
  • Broadfin Capital first reported a position in Collegium Pharmaceutical in Q2 2015 and held it in 1 quarter.
  • Broadfin Capital's Collegium Pharmaceutical position peaked at $5.3M in Q2 2015.
  • 49 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q3 2015.

Based on Broadfin Capital's 13F filing for Q3 2015, filed 16 Nov 2015.